A 14-amino-acid antimicrobial peptide from mudskipper fish killed drug-resistant MRSA and A. baumannii, prevented biofilm formation without inducing resistance, and outperformed both LL-37 and vancomycin in treating MRSA skin infections in mice.
Outperformed both LL-37 and vancomycin against MRSAIn a mouse skin infection model, this tiny 14-amino-acid fish peptide reduced MRSA bacterial load and improved wound healing better than the human body's own antimicrobial peptide and the gold-standard antibiotic
What the researchers found
Bolespleenin334-347 demonstrated broad-spectrum antibacterial activity against both Gram-negative (A. baumannii) and Gram-positive (S. aureus) bacteria. Its mechanism involves dual action: disrupting bacterial membrane integrity causing cellular content leakage and inducing endogenous reactive oxygen species (ROS) accumulation within bacteria.
The peptide effectively inhibited biofilm formation by both A. baumannii and S. aureus, and critically, long-term treatment did not induce resistance development. Activity was maintained against clinically multidrug-resistant strains. Most impressively, in a mouse model of MRSA-induced superficial skin infection, Bolespleenin334-347 showed superior efficacy to both LL-37 and vancomycin, significantly reducing bacterial load and promoting better wound healing. The peptide also demonstrated good thermal stability and sodium ion tolerance.
Why it matters
MRSA kills tens of thousands of people annually, and new antibiotics against it are desperately needed. Most antimicrobial peptides never advance beyond in vitro testing because they don't work well in live animals. This peptide cleared that critical hurdle — outperforming even vancomycin (the standard MRSA treatment) in a skin infection model. Its tiny size (14 amino acids), stability, and resistance to bacterial resistance development make it an unusually promising candidate for topical anti-MRSA therapy.
How the study worked
The peptide was identified from a gene in B. pectinirostris upregulated during bacterial challenge. Antibacterial activity was assessed by MIC determination against multiple species including drug-resistant clinical isolates. Mechanism studies used membrane integrity assays, ROS quantification, and electron microscopy. Anti-biofilm activity and resistance development were evaluated through serial passage and biofilm formation assays. In vivo efficacy was tested in a mouse MRSA skin infection model with comparison to LL-37 and vancomycin, measuring bacterial load and wound healing.
What this study cannot tell us
The mouse skin infection model tests only topical application, so systemic efficacy and safety remain unknown. The full antibacterial spectrum (MIC values against specific strains) was not detailed in the abstract. Pharmacokinetics, serum stability, and potential immunogenicity in mammals were not reported. The specific doses used in the mouse model versus LL-37 and vancomycin comparators were not provided, making it difficult to assess whether the comparison was at equivalent concentrations. Manufacturing costs for a peptide containing five consecutive arginines may be significant.
How to read the evidence
This is a comprehensive preclinical study progressing from peptide discovery through in vitro characterization to in vivo validation with clinical comparators (LL-37, vancomycin). The head-to-head comparison with established drugs in a relevant infection model is a strength, though translation to human clinical use requires further development.
When this study was published
Published in 2024, this is a very recent study representing the cutting edge of marine-derived antimicrobial peptide discovery.
The bigger picture
The search for new antibiotics is increasingly turning to organisms in extreme environments. Mudskippers are uniquely positioned as a peptide source — they transition between water and land, exposing them to diverse bacterial challenges that have driven the evolution of potent antimicrobial defenses. This study is notable not just for discovering a new peptide but for providing the complete preclinical package: broad-spectrum activity, mechanism of action, anti-biofilm effects, no resistance development, stability data, and in vivo superiority over established drugs. Published in Biochemical Pharmacology, it represents a serious antibiotic development candidate.
Questions still open
- Could Bolespleenin334-347 be developed as a topical cream or wound dressing for MRSA skin and wound infections?
- Does the five-consecutive-arginine motif contribute uniquely to its antimicrobial potency, and could it be incorporated into other peptide designs?
- Would this peptide maintain its superiority over vancomycin in deeper tissue or systemic MRSA infection models?
Common questions
Why would a fish peptide work against human infections?
Why is it significant that bacteria didn't develop resistance to this peptide?
Read the original research
A 14-amino acid cationic peptide Bolespleenin334-347 from the marine fish mudskipper Boleophthalmus pectinirostris exhibiting potent antimicrobial activity and therapeutic potential.
Biochemical pharmacology, 226, 116344
Citation
Bai, Yuqi; Zhang, Weibin; Zheng, Wenbin; Meng, Xin-Zhan; Duan, Yingyi; Zhang, Chang; Chen, Fangyi; Wang, Ke-Jian. (2024). A 14-amino acid cationic peptide Bolespleenin334-347 from the marine fish mudskipper Boleophthalmus pectinirostris exhibiting potent antimicrobial activity and therapeutic potential.. Biochemical pharmacology, 226, 116344. https://doi.org/10.1016/j.bcp.2024.116344